A Phase 1, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
Latest Information Update: 14 Nov 2024
Price :
$35 *
At a glance
- Drugs GSK 4528287 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors GSK
- 14 Nov 2024 New trial record